SCHEMBL3010898

SCHEMBL3010898

COc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.59
SMN1; SMN2 Q16637 7/20 0.59
ALDH1A1 P00352 5/20 0.58
L3MBTL1 Q9Y468 4/20 0.58
MAPT P10636 6/20 0.58
USP2 O75604 1/20 0.57
RECQL P46063 1/20 0.57
HSD17B10 Q99714 1/20 0.57
NPC1 O15118 5/20 0.56
MAPK1 P28482 5/20 0.56
TDP1 Q9NUW8 2/20 0.54
LMNA P02545 3/20 0.52
KCNQ1 P51787 1/20 0.52
AR P10275 3/20 0.51
HTT P42858 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005207 1.00 RAB9A (0.59) RAB9ASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL2998857 0.95 SMN1; SMN2 (0.65) RAB9ASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3011075 0.91 MAPT (0.54) RAB9ASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3016011 0.91 MAPT (0.61) RAB9ASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3015843 0.91 SMN1; SMN2 (0.60) RAB9ASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3011948 0.91 SMN1; SMN2 (0.60) RAB9ASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3013467 0.90 SMN1; SMN2 (0.59) RAB9ASMN1; SMN2ALDH1A1MAPTUSP2
SCHEMBL3016686 0.90 RAB9A (0.59) RAB9ASMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL3013260 0.90 RAB9A (0.59) RAB9ASMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL3013343 0.90 MAPT (0.66) RAB9ASMN1; SMN2ALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.